We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Diagnostic Antibodies and Proteins Detected with DNA Nanomachines

By LabMedica International staff writers
Posted on 27 Oct 2015
A nanoscale machine composed of synthetic DNA can be used for the rapid, sensitive and low-cost diagnosis of many infectious and autoimmune diseases, including human immunodeficiency virus (HIV) and rheumatoid arthritis (RA). More...


A versatile platform for the one-step fluorescence detection of both monovalent and multivalent proteins has been developed and is based on a conformation-switching stem-loop DNA scaffold that presents a small-molecule, polypeptide, or nucleic-acid recognition element on each of its two stem strands.

Scientists at the University of Rome Tor Vergata (Italy) working with their North American colleagues designed and synthetized a nanometer-scale DNA "machine" whose customized modifications enable it to recognize a specific target antibody. Their new approach promises to support the development of rapid, low-cost antibody detection at the point-of-care, eliminating the treatment initiation delays and increasing healthcare costs associated with current techniques. The protein-targeting sensor is composed of a fluorophore/quencher-modified DNA stem–loop system containing two single-stranded tails. To create a target-responsive sensor, these tails are hybridized with DNAs conjugated to an appropriate recognition element.

The binding of the antibody to the DNA machine causes a structural change or switch, which generates a light signal. The sensor does not need to be chemically activated and is rapid, acting within five minutes, enabling the targeted antibodies to be easily detected, even in complex clinical samples such as blood serum. The versatility of the platform was demonstrated by detecting five bivalent proteins (four antibodies and the chemokine platelet-derived growth factor) and two monovalent proteins (a Fab fragment and the transcription factor TATA Box Binding Protein (TBP) with low nanomolar detection limits and no detectable cross-reactivity.

Francesco Ricci, PhD, a professor and senior coauthor of the study, said, “One of the advantages of our approach is that it is highly versatile. This DNA nanomachine can be in fact custom-modified so that it can detect a huge range of antibodies; this makes our platform adaptable for many different diseases.” The materials needed for one assay cost about USD 0.15, making the approach very competitive in comparison with other quantitative approaches. The study was published on September 4, 2015, in the journal Angewandte Chemie.

Related Links:

University of Rome Tor Vergata



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.